---
title: "FriskaAi and Dexcom Enter CGM Data Integration Agreement"
description: "FriskaAi has entered into an agreement with Dexcom to integrate data from its Continuous Glucose Monitoring (CGM) systems into the FriskaAi platform. This integration aims to enhance diabetes manageme"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252882614.md"
published_at: "2025-08-13T13:30:00.000Z"
---

# FriskaAi and Dexcom Enter CGM Data Integration Agreement

> FriskaAi has entered into an agreement with Dexcom to integrate data from its Continuous Glucose Monitoring (CGM) systems into the FriskaAi platform. This integration aims to enhance diabetes management and preventive care by providing personalized health insights and recommendations. The FriskaAi platform, which is EHR-agnostic, utilizes advanced AI technology to analyze health data and alert patients and clinicians when action is needed. This collaboration is expected to empower patients and support physicians in managing chronic diseases more effectively.

ARLINGTON, VA / ACCESS Newswire / August 13, 2025 / FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into the FriskaAi platform. Under the agreement, data from Dexcom CGMs will be integrated with Friska Ai, the company's groundbreaking AI-powered healthcare platform supporting physicians and patients with actionable personalized care management programs.

FriskaAi is a physician-directed health and wellness platform that supports the management of diabetes and other chronic diseases by helping providers take an evidence-based approach to preventive care. The EHR-agnostic FriskaAi platform leverages advanced AI and mobile technology to generate personalized health insights and recommendations, empowering patients to take control of their health journey in partnership with their clinical team.

"Impacting more than 38 million Americans, diabetes has emerged as a major public health problem, and its effective management has become a foundational element of preventive medicine," says Shaji Nair, CEO of FriskaAi. "Dexcom's pioneering CGMs are vital tools not only for diabetes management but also for informing broader care decisions. FriskaAi is excited about the potential this integration with Dexcom presents to the physicians relying on our platform for chronic disease management and the patients seeking greater control over their health and wellness."

Dexcom CGMs use a small, wearable sensor to continuously measure and send glucose levels wirelessly to a smart device or receiver in real-time, without the need for fingerpricks. Dexcom CGMs also offer a suite of customizable alerts that can warn of high or low glucose levels and send predictive alerts to help users spend more time in range.

The FriskaAi mobile app securely integrates with Dexcom CGMs and other smart devices, as well as health apps, for analysis by the powerful HIPAA-compliant FriskaAi platform. That data, along with other clinical data and studies, is continuously monitored by sophisticated AI-powered algorithms that alert the patient when action is recommended and generate actionable reports for use by the clinician at the point of care to inform care decisions.

Aggregated health data is also analyzed within the FriskaAI platform to help physicians identify trends and risks within their patient populations, enabling more proactive and preventive care strategies.

**About FriskaAi**

FriskaAi is a powerful AI-enabled EHR-agnostic platform that helps physicians and other providers take an evidence-based approach to preventive care. The physician-initiated platform leverages advanced AI- and mobile technology to provide patients with personalized health insights and recommendations, empowering them to take control of their health journey in partnership with their clinical team. This aggregated health data, including information from patients' glucometers, other smart devices, and health apps, is continuously analyzed by advanced evidence-based algorithms that alert the patient when action is needed and provide clinicians with actionable reports to inform care decisions. FriskaAi also supports population health strategies by analyzing aggregated health data to identify trends and risks within a defined patient population. For more information, visit www.friska.ai.

**Media Contact:**

Michele Nachum

NPC Creative Services

michele@npccs.com

**SOURCE:** FriskaAi

View the original press release on ACCESS Newswire

### Related Stocks

- [DXCM.US - DexCom](https://longbridge.com/en/quote/DXCM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 德康醫療｜8-K：2025 財年 Q4 營收 12.6 億美元超過預期 |  | [Link](https://longbridge.com/en/news/275807118.md) |
| 德康醫療的 7.5 億美元 2025 年回購計劃在執行上存在不確定性，並且對股東價值的保證有限 | 德康醫療宣佈了一項 2025 年價值 7.5 億美元的股票回購計劃，但由於市場波動和競爭資本需求，其執行可能存在不確定性。無法保證此次回購將提升長期股東價值。儘管如此，華爾街對 DXCM 股票仍保持強烈買入的共識，評級為 17 個買入、1  | [Link](https://longbridge.com/en/news/275970360.md) |
| Dave Ramsey 在妻子發現丈夫秘密賭博輸掉了 12 萬美元后表示：‘他不值得信任’，儘管他的收入為 10 萬美元 | 一位芝加哥地區的教育工作者安妮發現，她的丈夫秘密地將他們的儲蓄中的 12 萬美元用於賭博，儘管他們的總收入約為 17.5 萬美元。為了重建財務狀況，她尋求建議，並瞭解到優先考慮安全和信任的重要性。主持人戴夫·拉姆齊和約翰·德隆尼強調，安妮需 | [Link](https://longbridge.com/en/news/276029278.md) |
| 7 位分析師對 DexCom 的看法 | 德康醫療（NASDAQ:DXCM）在過去三個月內獲得了 7 位分析師的混合評級，12 個月的平均目標價為 77.14 美元。最近的評估顯示出不同的情緒，一些分析師維持或提高了他們的評級，而另一些則降低了評級。關鍵見解包括 21.64% 的收 | [Link](https://longbridge.com/en/news/275896619.md) |
| 米歇爾·奧巴馬分享了一條至關重要的關係建議——心理治療師也參與了討論 | 米歇爾·奧巴馬建議情侶在同居前等待幾年，強調愛情需要時間來發展。在她的播客中，她指出，過早同居可能無法讓伴侶充分了解彼此。持證治療師也表示，這一決定應基於關係動態，而不僅僅是時間。他們建議在搬入之前討論財務、目標和家庭責任，強調期望的一致性 | [Link](https://longbridge.com/en/news/275949595.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.